CJC-1295

A modified GHRH analog used in research as a long-acting growth hormone-releasing hormone. The DAC variant has an extended half-life via albumin binding, while non-DAC versions act for shorter durations.

What does CJC-1295 mean in peptide research?

A modified GHRH analog used in research as a long-acting growth hormone-releasing hormone. The DAC variant has an extended half-life via albumin binding, while non-DAC versions act for shorter durations. This term is part of the broader field of peptide research, which encompasses both FDA-approved therapeutic peptides and research-grade compounds used in scientific investigation.

Why this term matters

Understanding CJC-1295 is foundational for anyone reviewing peptide research literature, comparing different research compounds, or following regulatory developments in this field. The term appears across pharmacology textbooks, FDA documentation, and clinical trial reports.

Where to learn more

For deeper context, see our peptide research articles:

• What Are Peptides? Comprehensive Introduction
• Research-grade vs Clinical-grade Peptides
• FDA Peptide Regulatory Status 2026
• Full Peptide Glossary Article